According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the information submitted to the U.S. Food and Drug Administration (“FDA”) for the development of a COVID-19 vaccine candidate was insufficient to support an Emergency Use Authorization (“EUA”);
- Ocugen would not file an EUA with the FDA; and
- as a result of the foregoing, Ocugen’s financial statements, as well as defendants’ statements about Ocugen’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.